235 related articles for article (PubMed ID: 38683573)
21. Remdesivir for the treatment of COVID-19.
Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
[TBL] [Abstract][Full Text] [Related]
22. A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports.
Sadat Larijani M; Doroud D; Banifazl M; Karami A; Bavand A; Ashrafian F; Ramezani A
Eur J Med Res; 2023 Nov; 28(1):542. PubMed ID: 38008729
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.
Mostafavi E; Eybpoosh S; Karamouzian M; Khalili M; Haji-Maghsoudi S; Salehi-Vaziri M; Khamesipour A; Jalali T; Nakhaeizadeh M; Sharifi H; Mansoori Y; Keramat F; Ghodrati S; Javanian M; Doroud D; Omrani MD; Asadi H; Pouriayevali MH; Ghasemian R; Farshidi H; Pourahmad M; Ghasemzadeh I; Mounesan L; Darvishian M; Mirjalili MR; Toledo-Romani ME; Valenzuela-Silva C; Verez-Bencomo V; Gouya MM; Emadi-Koochak H; Haghdoost AA; Biglari A;
JAMA Netw Open; 2023 May; 6(5):e2310302. PubMed ID: 37133864
[TBL] [Abstract][Full Text] [Related]
24. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.
Nevitt SJ; Sudell M; Tudur Smith C; Marson AG
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012065. PubMed ID: 31233229
[TBL] [Abstract][Full Text] [Related]
25. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.
Chu DK; Abrams EM; Golden DBK; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Shaker M; Greenhawt M
JAMA Intern Med; 2022 Apr; 182(4):376-385. PubMed ID: 35188528
[TBL] [Abstract][Full Text] [Related]
26. Interventions to increase COVID-19 vaccine uptake: a scoping review.
Andreas M; Iannizzi C; Bohndorf E; Monsef I; Piechotta V; Meerpohl JJ; Skoetz N
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015270. PubMed ID: 35920693
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.
Ozdarendeli A; Sezer Z; Pavel STI; Inal A; Yetiskin H; Kaplan B; Uygut MA; Bayram A; Mazicioglu M; Unuvar GK; Yuce ZT; Aydin G; Aslan AF; Kaya RK; Koc RC; Ates I; Kara A
Vaccine; 2023 Jan; 41(2):380-390. PubMed ID: 36460536
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
29. Association of seizure with COVID-19 vaccines in persons with epilepsy: A systematic review and meta-analysis.
Rafati A; Jameie M; Amanollahi M; Jameie M; Pasebani Y; Sakhaei D; Ilkhani S; Rashedi S; Pasebani MY; Azadi M; Rahimlou M; Kwon CS
J Med Virol; 2023 Sep; 95(9):e29118. PubMed ID: 37732629
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis.
Chen JJ; Lee TH; Tian YC; Lee CC; Fan PC; Chang CH
JAMA Netw Open; 2021 Oct; 4(10):e2131749. PubMed ID: 34709385
[TBL] [Abstract][Full Text] [Related]
31. Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis.
Behrouzi B; Bhatt DL; Cannon CP; Vardeny O; Lee DS; Solomon SD; Udell JA
JAMA Netw Open; 2022 Apr; 5(4):e228873. PubMed ID: 35486404
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of controlled and randomized clinical trials.
Beladiya J; Kumar A; Vasava Y; Parmar K; Patel D; Patel S; Dholakia S; Sheth D; Boddu SHS; Patel C
Rev Med Virol; 2024 Jan; 34(1):e2507. PubMed ID: 38282394
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
[TBL] [Abstract][Full Text] [Related]
34. Vaccines for preventing herpes zoster in older adults.
Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
[TBL] [Abstract][Full Text] [Related]
35. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review.
Nevitt SJ; Tudur Smith C; Weston J; Marson AG
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001031. PubMed ID: 29952431
[TBL] [Abstract][Full Text] [Related]
36. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.
Nevitt SJ; Tudur Smith C; Marson AG
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD003615. PubMed ID: 30350354
[TBL] [Abstract][Full Text] [Related]
37. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure.
Leone MA; Giussani G; Nevitt SJ; Marson AG; Beghi E
Cochrane Database Syst Rev; 2021 May; 5(5):CD007144. PubMed ID: 33942281
[TBL] [Abstract][Full Text] [Related]
38. Remdesivir for the treatment of COVID-19.
Grundeis F; Ansems K; Dahms K; Thieme V; Metzendorf MI; Skoetz N; Benstoem C; Mikolajewska A; Griesel M; Fichtner F; Stegemann M
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014962. PubMed ID: 36695483
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
40. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
